✦ LIBER ✦

The relevance of stable disease (SD) as a surrogate end-point in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib (E) as the second/third line

✍ Scribed by Grossi, F.; Sini, C.; Barletta, G.; Rijavec, E.; Genova, C.; Dal Bello, G.; Pronzato, P.; Venturino, P.; Pappagallo, G.

Book ID: 119320872
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 63 KB
Volume: 77
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2012.05.056

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

6612 POSTER Disease stabilization (SD) a

6612 POSTER Disease stabilization (SD) as a surrogate end-point in advanced non-small-cell lung cancer (NSCLC) patients treated with erlotinib (E) or gefitinib (G)

✍ Grossi, F.; Defferrari, C.; Brianti, A.; Dal Bello, M.G.; Loprevite, M.; Catania 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Clinical surrogate markers of survival i

Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second–third line erlotinib

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

Activity and safety of erlotinib as seco

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

✍ David Rossi; Donatella Dennetta; Marcello Ugolini; Vincenzo Catalano; Paolo Ales 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 129 KB

Randomized Phase III Trial of Erlotinib

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

✍ Kawaguchi, T.; Ando, M.; Asami, K.; Okano, Y.; Fukuda, M.; Nakagawa, H.; Ibata, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 183 KB

9140 Evaluation of treatment adherence,

9140 Evaluation of treatment adherence, persistance, and quality of life in patients with advanced non-small cell lung cancer (ANSCLC) treated with erlotinib (e) as second-line therapy

✍ Gebbia, V.; Russo, P.; Mancuso, G.; Arcara, C.; Borsellino, N. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

29 The use of erlotinib as second line t

29 The use of erlotinib as second line treatment in patients with non-small cell lung carcinoma (NSCLC) in Birmingham. Does EGFR play a role?

✍ Reeve, N.; Cook, M.; Keshri, A.; O'Sullivan, B.; Taniere, P.; Ghafoor, Q. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 149 KB